Topiramate for smoking cessation.
Due to its AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid)/kainate antagonism, topiramate would be particularly interesting in addiction treatment. Flexible-dose topiramate was prescribed to 13 smokers (10 smokers who wanted to stop smoking, and three who received topiramate for other reasons). Six out of 13 smokers were abstinent at 2 months and two more subjects had reduced their cigarette consumption by >50%. With one exception, temporary reduction of the number of smoked cigarettes preceded definitive abstinence at month 2. Three more subjects who achieved a momentary reduction had, however, to interrupt the treatment due to intolerable side-effects. Controlled trials are needed to confirm these preliminary observations.
Khazaal
Yasser
Y
University Department of Adult Psychiatry, Prilly, and Department of Community Medicine and Public Health, University Hospital, Lausanne, Switzerland. yasser.khazaal@hospvd.ch
Cornuz
Jacques
J
Bilancioni
Romain
R
Zullino
Daniele Fabio
DF
D000328:Adult; D016739:Behavior, Addictive / Q000188:drug therapy*; D005260:Female; D005632:Fructose / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D010865:Pilot Projects; D018091:Receptors, AMPA; D016540:Smoking Cessation; D000074606:Smoking Prevention; D000077236:Topiramate; D018350:alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid / Q000819:agonists
D018696:Neuroprotective Agents; D018091:Receptors, AMPA; D000077236:Topiramate; D005632:Fructose; D018350:alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid